SCHEMBL454241

SCHEMBL454241

COC(=O)c1cc(-c2ccc(F)cc2)c(N)c([N+](=O)[O-])c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.45
PTGS1 P23219 2/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
ERN1 O75460 1/20 0.43
IKBKB O14920 1/20 0.42
MYC P01106 2/20 0.42
MAX P61244 2/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
PTGS2 P35354 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
TTR P02766 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL453504 0.86 ERN1 (0.52) VCAM1PTGS1SLC6A4SLC6A3ERN1
SCHEMBL452451 0.81 KDM4E (0.52) PTGS1SLC6A4SLC6A3IKBKBKDM4E
SCHEMBL5217104 0.81 VCAM1 (0.55) VCAM1KDM4EMEN1KMT2AMAPT
SCHEMBL452184 0.80 PTGS1 (0.49) PTGS1SLC6A4SLC6A3IKBKBKDM4E
SCHEMBL2949599 0.78 ERN1 (0.51) VCAM1PTGS1SLC6A4SLC6A3ERN1
SCHEMBL14667928 0.78 MAPT (0.43) VCAM1KDM4EMEN1KMT2AMAPT
SCHEMBL29930566 0.77 VCAM1 (0.51) VCAM1KDM4EMEN1KMT2AMAPT
SCHEMBL5217118 0.77 VCAM1 (0.51) VCAM1KDM4EMEN1KMT2AMAPT
SCHEMBL20495264 0.77 TDP1 (0.47) PTGS1IKBKBMEN1KMT2AMAPT
SCHEMBL443612 0.76 ALDH1A1 (0.51) VCAM1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed
EP-2410857-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
WO-2010111058-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 VCAM1 1196/4885PTGS1 294/4885SLC6A4 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.